Silence Therapeutics
SLN
9.39
-0.43
-4.38%
Silence Therapeutics
US · SLN
#3615 by market cap
9.39
-0.43
-4.38%
Live - 5344 symbols - heartbeat 293s ago
· 2026-10-08 10:00
Pre-market
9.95
+1.32%
After-hours
9.82
0.00%
- Market cap
- 583.63M
- P/E (TTM)i
- -7.28
- P/Bi
- 15.17
- EPSi
- -1.89
- Div yieldi
- 0.00%
- 52W posi
- 39%
Reader sentiment
Are you bullish or bearish on SLN?
Anonymous reader poll. Unscientific, not investment advice.
About Silence Therapeutics
Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.
- Founded
- 1994
- CEO
- Mr. Iain Gladstone Ross
- Employees
- 88
- Headquarters
- London, Greater London, United Kingdom of Great Britain and Northern Ireland (the)
- Fiscal year end
- 12-31
- Website
- silence-therapeutics.com
Company profile
- Exchange
- US
- Symbol
- SLN
- Market-cap rank
- #3615
- Market cap
- 583.63M
- Float cap
- 471.11M
- Shares out
- 62.15M
- Float shares
- 50.17M
Sectors & themes
Quote time 2026-10-08 10:00:12 · For reference only, not investment advice and not tailored to your situation.